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Background: Fibromyalgia Syndrome (FMS) is a frequent comorbidity in Irritable Bowel Syndrome (IBS) patients
with a higher functional bowel disorder severity index (FBDSI). We tested the possibility that mild to severe IBS
patients without FMS would have a graduated visceral and somatic perception, and the presence of FMS would
further enhance somatic, but conversely attenuate visceral perception.
Our aim was to study visceral and somatic sensitivity in mild IBS patients and in severe IBS patients with or
without FMS.
Methods: Eleven mild IBS and 19 severe IBS with and without FMS patients were studied. Somatic and visceral
stimuli were applied in each patient by means of electrical stimulations at active and control sites and by means of
an electronic barostat in the rectum. Thresholds for discomfort and perception cumulative scores were measured.
Results: Mild and severe IBS patients without FMS demonstrated a significantly lower somatic perception
cumulative score than severe IBS patients with FMS at active site. Conversely only severe IBS patients without FMS
had significantly lower visceral thresholds for discomfort than mild IBS patients and severe IBS patients with FMS.
Conclusions: The presence of co-existing FMS or greater FBDSI affects somatic and visceral perception in a graded
fashion across IBS patients.
Keywords: Adult, Female, Irritable bowel syndrome/complications, Irritable bowel syndrome/physiopathology, Male,
Questionnaires, Severity of illness index, Fibromyalgia, Functional bowel disorder severity index (FBDSI)Background
Irritable bowel syndrome (IBS) is a functional intestinal
disorder characterized by chronic pain or discomfort in
the abdomen associated with altered bowel habits [1].
Patients with IBS often have at least one co-morbid
somatic complaint and many IBS patients meet diagnostic
criteria for other functional disorders [2,3]. Interestingly,
patients with IBS and another functional disorder, in
comparison with patients with only IBS, have more
severe IBS symptoms, a higher rate of psychological
comorbidity such as depression, anxiety and somatization,
greater impairment of quality of life, and more illness-
related work absenteeism [4]. In particular, there is a* Correspondence: piovino@unisa.it
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article, unless otherwise stated.significant association between IBS and fibromyalgia
syndrome (FMS) [5,6]. FMS is chronic non-articular
rheumatism where a reproducible physical finding, the
presence of tender points, is associated with character-
istic symptoms of generalized muscular aches and pains
[7]. It has been demonstrated that the association of
IBS and FMS depends on the level of severity scored by
the functional bowel disorder severity index (FBDSI)
more than on the predominant symptom of the intestinal
disorder [8,9]. In this respect, the FBDSI is sensitive
enough to distinguish among the different groups, mani-
festing a logical sequence of illness severity with incre-
mental worsening, from healthy controls through IBS
non-patients, to patients with mild IBS only that never
showed FMS, and, finally, more severe IBS patients with
concomitant FMS [8,9].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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epidemiology (female predominance), pathophysiological
hypothesis (inflammation, hypersensitivity, impaired central
processing of afferent sensory information, role of sero-
tonin, psychological distress and somatization, and the role
of stress and life events), diagnosis (symptom-based), the
central role of the patient-physician relationship in therapy,
and common therapeutic modalities.
Interestingly, mounting evidence suggests similar changes
in pain processing mechanisms. 35–60% of IBS patients
had visceral hypersensitivity, whilst studies on somatic pain
perception in IBS patients showed contrasting results.
Originally IBS patients without FMS showed somatic
hyposensitivity at active somatic tender points, non-tender
control sites and the T-12 dermatome [10]. Subsequent
studies have demonstrated normal skin sensitivity to
electrical stimuli at control points [11] or even somatic
hyperalgesia with electrical stimuli at active points and
areas of pain referral and thermal stimuli on hand and
foot. [11,12]. The coexistence of IBS with FMS that
corresponds to a greater illness severity lowered the
thresholds to thermal (hand and foot) [13] and electrical
stimulation [14] at control (hand and elbow) and active
sites (trapezius). Peripheral and central neural dysregu-
lation or both have been involved in explaining these
abnormalities in visceral and somatic sensitivity.
In addition, psychological symptoms were shown to
contribute to these sensory dysfunctions and may be in-
volved in pain modulation processes that are related to
chronic pain [15,16]. Therefore, this altered sensitivity in
IBS patients is consistent with the existence of multiple
pathophysiological disorders in IBS patients [17].
Previous studies have reported that the severity of IBS
symptoms was positively, although weakly correlated to
altered rectal perception [18,19] and to alteration of pain
processes [16]; others failed to find a significant correl-
ation between visceral hypersensitivity and most IBS
symptom severity [20], although, many of these studies
were limited by the use of non-validated questionnaires.
Thus, characterizing the individual patient on the basis
of a severity illness instrument already validated would
be desirable to overcome the effects of the heterogeneity
in pathophysiological mechanisms in IBS [17].
Nowadays, despite the pathophysiological link between
IBS and FMS is very interesting and clinically relevant,
patients with different IBS severity and the coexistence
of FMS have rarely been investigated in the same study
to better understand the interactions between both
conditions. We tested the possibility that mild to severe
IBS patients without FMS would have a graduated
visceral and somatic perception, and the presence of
FMS co-existing with a more severe IBS would further
enhance somatic perception, but conversely attenuate
the visceral one.Our aim was to study visceral and somatic sensitivity
in mild IBS patients and in severe IBS patients with or
without the coexistence of FMS.
Methods
Participants
Thirty IBS patients (19 women, mean age ± SD: 36.4 ±
10.3 yr, range) participated in the study, after giving their
informed consent. The study protocol had previously been
approved by the medical ethical committee of Federico II
University of Naples.
IBS patients were recruited from an outpatients clinic de-
voted only to functional gastrointestinal disorders (FGIDs).
At the same time, two rheumatologists observed all patients
recruited for this study. The diagnosis of IBS was made on
the basis of the Rome III Criteria [21], together with the
exclusion of any organic disease; all patients had an accur-
ate medical history - a physical examination including a
rectal examination and routine biochemical tests. Patients
with infectious diarrhoea, urological infections, lactose
intolerance, parasite infections, helicobacter pylori infec-
tion, rectal blood loss, encopresis, neurological or psychi-
atric diseases and any other organic cause of abdominal
pain were excluded from the study.
The severity of IBS was scored using the validated func-
tional bowel severity disorder index (FBSDI) developed by
Drossman et al. [22], which provides an easy-to-use scale
to appraise illness severity in these patients. In fact, the
FBDSI is a measure primarily of pain reporting and behav-
ior. It is comprised of three variables: current pain (by
visual analog scale), diagnosis of chronic abdominal pain,
and number of physician visits in the past 6 months.
Severity is rated as mild (1–36 points), moderate (37–110
points), and severe (≥111 points). Details of the index
calculation of the index are presented in the original
article [22]. FMS was diagnosed by widespread pain and
tenderness in a minimum of 11 of 18 defined tender
points (American College of Rheumatology classification
criteria) [7]. Patients with signs of inflammatory arthritis
documented by clinical, serological and radiological evalu-
ation were excluded. None of the participants were taking
serotonin antagonists, pain medications, serotonin uptake
inhibitors, or tricyclic antidepressants for at least 3 weeks
prior to the study. Subjects were instructed to refrain from
the use of any medication for 72 hrs before their sessions.
Patients were excluded if they had serious, unstable med-
ical condition, insulin-dependent diabetes mellitus, major
psychiatric diagnosis, previous history of drug or alcohol
abuse 6 months prior to screening and if they had under-
gone previous abdominal surgery except appendectomy.
Somatic perception measurements
Somatic perception was evaluated using a constant
current with TENS I (100 Hz, 100 μs) modality through
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consists of intermittent phasic stimuli of 1 mA and 20-s
duration and separated by an interval of 30 s from 0 up
to a respective threshold for discomfort. Two specific
test points were chosen: the non-dominant elbow (the
midpoint of the elbow crease in the cubital fossa) as the
non-tender point (control site), and the right trapezius
(midpoint of the trapezius muscle) as the tender point
(active site). At the selected test site, only one somatic
stimulus (sham vs electrical stimuli) was given at a time
in a random order. In this protocol a sham stimulus
consists of a stimulus of 0 mA = no current output and
20-s duration. Subjects were not informed about specific
characteristics or the magnitude (mA) of the individual
stimuli applied. For somatic perceptions assessment, after
each somatic stimulus, the participants were asked to fill
in the perception questionnaire.
Visceral perception measurements
Rectal barostat studies to assess sensitivity were performed
as previously reported [23]. Briefly, the barostat maintains a
constant pressure on the inside of a bag containing air by
means of feedback. The feedback mechanism consists of a
strain-gauge connected to an injection/aspiration system by
means of a relay. In our study both the strain gauge and the
injection/aspiration system were independently connected
by a double-lumen polyvinyl tube (12 F, Vygon, Belgium)
to a spherical ultra thin bag (capacity 600 ml). Before and
after each study, the balloon was checked for leakage.
Accordingly to the standardized barostat procedures [24]
that advice the cleansing of the studied segment of the gut
from any residual content, the evening before the study’s
day subjects underwent the application of an enema
(sodium diocthylsulfosuccinate/sorbitol, 120 mL) [22].
To our knowledge no potential effects of the chemical
substances in the enema have been reported.
After at least a 12 hour fast the carefully folded and
lubricated bag was introduced through the anus into the
rectum with subjects placed in the left lateral position. A
dial allows the selection of the desired pressure level. To
unfold the intrarectal bag, one lumen of the polyvinyl
tube was connected to a pressure transducer of the
barostat device and the bag was slowly inflated through
the other lumen of the tube with 200 ml of air under
controlled pressure (<20 mmHg). With the balloon
inflated, the catheter was pulled back against the pelvic
floor and then the bag was completely deflated and
connected to the barostat device. Pressure and volume
within the bag were continuously recorded. After a
15 minute adaptation period a stepwise protocol (incre-
ments in the rectal bag of 1 mmHg and 60 seconds of
duration) was selected to measure the minimal distending
pressure (MDP) defined as the first pressure inducing an
intrarectal volume >30 ml and at which the influence ofbreathing on the volume was visible [24,25]. This pressure
level accounted for intraabdominal pressure. Afterwards,
an intermittent phasic-deflation (distensions) protocol was
administered by using the ascending methods of limits
with a tracking protocol. Visceral stimuli of 4 mmHg were
applied with an interval of 120 seconds, from MDP up
to the respective thresholds of discomfort or until the
intrabag volume was greater than 550 ml. When the
discomfort threshold was reached, a tracking protocol
began. The latter consists of successive intermittent
phasic distensions occurring in an unpredictable order,
at the same or at a lower discomfort pressure, depending
on the subject’s responses; in case the distension received
a sensation score lower than the discomfort threshold,
then the subsequent distention used the same or a higher
pressure (in a random order), until the discomfort thresh-
old was reached again. At level at which the patients
reported discomfort, the relative pressures were randomly
measured three times and then averaged to produce
one value.
At each pressure step, intrabag volume was averaged
over the last 30 seconds before the next pressure step.
The volume-pressure curve was constructed starting
from MDP and the rectal compliance (ΔV/ΔP) was used
for analysis. During the last 30 seconds of each stimulus
the participants were asked to fill in the perception
questionnaire.
Somatic and visceral perception questionnaires
Somatic and visceral perception were tested using graded
standardized questionnaires [14,23,26]. Shaking, pricking
with a needle, tingling and burning were the four sensa-
tions included in the somatic perception questionnaire,
while the visceral perception questionnaire included
bloating, colicky, tenesmus and urge to defecate. Before
examinations the questionnaires were fully explained to
the participants. The participants were told that after each
stimulus the investigator would have ask them to mark in
the questionnaire any perceived sensation. Participants
were also told, both during somatic and visceral stimula-
tions, to specify any other perceived sensation in an open
box in the correspondent questionnaire. Any somatic or
visceral sensation was independently evaluated on a
graphic rating scale that combines visual descriptors on
a visual analog scale graded from 0 to 6. Each participant
received standard instructions, specifying that score 0
represented the absence of perception, score 5 represented
a sensation of discomfort and score 6 represented a sensa-
tion of pain that caused an immediate interruption of the
stimulus. Every somatic or visceral sensation was evalu-
ated on the scale, on the basis of its perceived intensity,
and orientation descriptors were provided indicating that
score 1 represented vague perception of light intensity,
score 2 represented definite perception of light intensity,
Table 1 Demographic variables for IBS patients with and
without FMS





Patients (n) 11 12 7
Gender (female), (%) 6 (54) 6 (50) 7 (100) p = 0.09
Age (mean ± SE) 35.9 ± 3.0 35.2 ± 3.4 39.4 ± 3.3 p = 0.70
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tion of moderate sensation, respectively. Participants
were also told that if needed, they could indicate half
unit scores on the scale, in such a way that scores of
intensity were really 12. In each subject the perception
score corresponding to each somatic or visceral stimulus
was computed and the cumulative score of the common
responses was used for comparisons [14,23,27]. Discom-
fort threshold was defined as the first stimulus (electrical
stimulus or rectal pressure) that induced a perception
score of ≥5. This type of questionnaire has been previously
validated in detail by showing its discrimination power
and reproducibility in identifying changes in perception
in response to increasing stimuli, under conditions that
modify perception, and in groups of hypersensitive patients
as compared to healthy controls [28,29].
Experimental design
Examinations were performed in a quiet, isolated room by
the same investigator. Somatic and visceral perception
protocols were tested in each patient on different days and
in random order, separated by an interval of at least 1 wk.
Statistical analysis
Data are presented as Mean ± SE, unless otherwise indi-
cated. χ2 test and analysis of variance (ANOVA) adjusted
for age and gender followed by one-way ANOVA for
multiple comparisons (Bonferroni)) were used to compare
categorical and continuous data, respectively. Spearman
correlation test (R) was used when appropriate. Signifi-
cance was expressed at p < 0.05 level. The SPSS software
package for Windows (release 15.0.1; SPSS Inc, Chicago,
IL, USA) was used for statistical analysis.
Based on our previous study [14], if the mean difference
is 6.7(severe vs mild IBS) and the common within-group
standard deviation is 5.2 to find a difference between
somatic perception scores using a two-sided test with a
significance level of 5% and a power of 80%, it was esti-
mated that a minimum of 10 patients would have been
required in each group.
Results
Patients
11 mild IBS (6 F, age 35.9 ± 3.0 yrs), 12 severe IBS without
FMS (6 F, age 35.2 ± 3.4 yrs), and 7 severe IBS with FMS
patients (7 females, age 39.4 ± 3.3), underwent somatic
and visceral protocol. Gender and age distribution were
not significantly different among groups (χ2 test, p = 0.09
and Student t test, p = 0.7) (Table 1).
Symptomatic response to somatic stimuli
TENS I stimuli induced increased somatic perception
in all IBS patients. Thresholds for discomfort did not
significantly differ among mild IBS, severe IBS withoutFMS and severe IBS with FMS at active [25.4 ± 2.2 (16–34)
vs 24.9 ± 2.9 (14–44) vs 19.8 ± 2.6 (13–30)] and control
sites [20.8 ± 2.4 (11–36) vs 18.6 ± 2.8 (12–35) vs 14.6 ± 2.4
(8–23)] after adjusting for covariates: gender and age
(ANOVA, p = 0.4 and 0.3, respectively). Gender and age
did not significantly relate to the thresholds for discom-
fort at active and control sites. There was a lack of
significant correlation between IBS severity and somatic
thresholds for discomfort (R = −0.286, p = 0.2 at control
and R = −0-09, p = 0.7 at active sites, respectively). The
somatic perception cumulative score was calculated from
0 to 8 mA, which was used as the upper limit because one
patient experienced discomfort at that level. The somatic
perception cumulative score was significantly different
among groups after adjusting for covariates: gender and
age at active site (ANOVA, p = 0.006) and control site
(ANOVA, p = 0.03). Gender and age did not significantly
relate to the somatic perception cumulative score at active
and control sites. At active site mild and severe IBS
patients without FMS demonstrated a significantly lower
somatic perception cumulative score than severe IBS
patients with FMS [1.0 ± 0.4 (0–4) and 1.8 ± 0.6 (0–6)
vs 9.3 ± 3.2 (2–24) respectively, m ± SE (min-max),
Bonferroni test, p < 0.05], whilst at control site only
mild IBS patients without FMS showed a significantly
lower somatic perception cumulative score compared
to severe IBS with FMS [2.6 ± 1.1(0–10) vs 8.5 ± 1.6(3–14),
Bonferroni test p < 0.05] (Figure 1), whilst no significant
difference was reached in comparison to severe IBS patients
without FMS [3.9 ± 1.2 (0–10)].Symptomatic response to visceral stimuli
Isobaric rectal distensions induced increased perception of
symptoms in all IBS patients. Thresholds for discomfort
were significantly different among groups after adjusting
for covariates: gender and age (ANOVA p < 0.001). Gen-
der and age did not significantly relate to the thresholds
for discomfort. In detail, severe IBS patients without FMS
had significantly lower thresholds for discomfort than
mild IBS patients [17,8 ± 1.4 (12–24) vs 29.3 ± 2.1 (19–37),
Bonferroni test p < 0.05], and severe IBS patients with
FMS [26.2 ± 2.1(20–35), Bonferroni test p < 0.05], whilst
no differences were found between severe IBS patients
with FMS and mild IBS.
Figure 1 Somatic thresholds for discomfort did not significantly differ among groups at active and control sites (p = 0.4 and 0.3,
respectively). The somatic perception cumulative score was significantly different among groups at active and control sites (p = 0.006 and
p = 0.03, respectively). In detail, at active site mild and severe IBS patients without FMS demonstrated a significantly lower somatic perception
cumulative score than severe IBS patients with FMS, whilst at control site only mild IBS patients showed a significantly lower somatic perception
cumulative score compared to severe IBS with FMS.
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above MDP, which was used as the upper limit for the
calculation of visceral perception cumulative score and
compliance. The visceral perception cumulative score
was significantly different among groups after adjusting
for covariates: gender and age (ANOVA, p = 0.03). Gender
and age did not significantly relate to the visceral per-
ception cumulative score. In detail, severe IBS patients
without FMS had a significantly higher visceral perception
cumulative score than mild IBS patients [23.2 ± 2.9
(11.5-37) vs 12.3 ± 1.98 (2.5-19.5), Bonferroni test p < 0.05]
(Figure 2), whilst no significant difference was reached in
comparison to severe IBS patients with FMS [14.3 ± 2.8
(5–23)].Rectal function
The volume-pressure relationship in response to step-
wise increments in intrarectal pressure was linear in
IBS patients (individual r from 0.98 to 1.00). MDP was
not significantly different in mild IBS, severe IBS and
IBS and FMS patients (5.7 ± 1.3 mmHg, 4.8 ± 1.1 mmHg,4.8 ± 2.1 mmHg respectively, p = 0.9). Rectal compliance
was not significantly different among groups.
Discussion
Visceral hypersensitivity, which is noticeable through re-
duced threshold for pain, increased intensity of sensations
and/or exaggerated viscerosomatic referral in response to
colonic distension, is considered to be a biologic marker
for IBS and it is found in 35–60% of IBS patients [30,31].
In numerous IBS studies controlled rectal balloon dis-
tension by means of an electronic barostat has been used
for reaching the discomfort threshold [18,23,24,28,29,32].
A significant correlation between the symptom severity
and rectal perception, that is independent from gender,
has already been demonstrated in IBS patients [18,19].
Importantly, the alteration of pain processes is strongly
related to IBS symptoms, suggesting that altered pain
processes may contribute to the pathophysiology of IBS
[16]. To our knowledge, visceral and somatic sensitivity
have still not been sufficiently investigated in patients
selected for different IBS severity and coexistence of
FMS. The results of our study demonstrated that mild
Figure 2 Visceral thresholds for discomfort were significantly different among groups (p < 0.001). Severe IBS patients without FMS had
significantly lower thresholds for discomfort than mild IBS patients (p < 0.05), and severe IBS patients with FMS (p < 0.05), whilst no differences were
found between severe IBS patients with FMS and mild IBS. The visceral perception cumulative score was significantly different among groups
(p = 0.03). In detail, severe IBS patients without FMS had a significantly higher visceral perception cumulative score than mild IBS patients (p < 0.05).
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graduated visceral sensitivity; however, the presence of
FMS that co-exists only with a more severe IBS attenu-
ated visceral sensitivity. Furthermore, the cutaneous
sensitivity to electrical stimuli was significantly lower in
severe IBS patients with FMS as co-morbidity, whilst it
did not significantly increase along with the severity of
IBS. No correlation was found between the somatic
thresholds for discomfort and the severity of IBS at
control and active sites.
It is well known that FMS, an extraintestinal chronic
pain disorder characterized by widespread pain, is fre-
quently associated with IBS patients with higher severity
of illness [8,9]. Importantly, somatic mechanical hyper-
algesia is a characteristic feature of so-called “tender
points” which are a hallmark of FMS and part of the
1990 classification criteria of the American College of
Rheumatology for this syndrome [7]. There is a large
body of evidence for a generalized lowering of somatic
pressure pain thresholds in FMS patients [33,34], and
the mechanical allodynia of FMS patients is not limited
to tender points, but appears to be widespread [35]. In
addition, almost all studies of FMS patients have shown
abnormalities in pain sensitivity while using different
methods of somatic sensory testing. It has been previously
demonstrated that IBS patients have somatic hypoalgesia
to mechanical stimuli [10] and the presence of FMS com-
bined with higher severity of IBS influence the perception
of somatic stimuli induced by TENS [14]. Conversely,other studies demonstrated that patients with IBS may
also have cutaneous hyperalgesia. Caldarella et al. [11]
found in IBS patients a normal skin sensitivity to electrical
stimuli, but lowered pain thresholds at the subcutis and
muscle when compared to healthy controls (HC); whereas
IBS patients with FMS or patients with FMS alone had
significantly lower pain thresholds than HC even at skin
level. In another study by Moshiree et al., IBS + FMS
patients had enhanced thermal sensitivity compared to
IBS only patients during foot immersion in hot water [13].
Taking these studies together reinforced the concept
that IBS patients may also have somatic hypersensitivity
depending on the presence of comorbid FM or greater
illness severity [36]. The lack of significant differences in
somatic perception between mild and severe IBS patients
in this study could be in apparent disagreement with
the results of our previous study, in which, however,
the presence of FMS could have altered the type of
somatosensory perceptual alteration in IBS patients and
played a confounding role in the relationships between
discomfort thresholds and perception cumulative scores
versus IBS severity subgroups [14]. Moreover, it has been
already established that differences in testing procedures
and stimulus modalities such as mechanical, electrical,
thermal and ischemic stimuli could provoke different
results in somatic perception. For example, mechanical
stimuli did not reveal any evidence of somatic hypersensi-
tivity in either IBS patients or HC [10,37]. Alternatively,
there may be subgroups of IBS patients who differ in their
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interestingly, among subsets of IBS patients with thermal,
ischemic, and cold pressor hypersensitivity a minimal
overlap between groups was disclosed [37], suggesting
different underlying mechanisms. Less is known about
the changes in visceral sensitivity when IBS is associated
with FMS. In a previous study IBS and IBS with FMS
had significantly lower discomfort thresholds to rectal
distention (increased visceral sensitivity) compared to
HC, while FMS only patients were normosensitive at
the visceral level [11]. One of the major limitations of
this study, as enhanced by the same Authors, was the
recruitment of mostly severe IBS patients, according to
a higher number of positive tender points that should
correspond to a higher level of severity [8,9]. Thus, this
group of patients is at a more advanced stage of the
disease, which includes some preclinical features of FMS.
In this study to overcome this limitation we evaluated
mild IBS patients and severe IBS patients with or without
concomitant FMS selected using the FBDSI to eventually
disclose the differences among groups. The FBDSI is a
measure primarily of pain reporting and behavior. It
demonstrates known groups’ discriminant validity by
differentiating IBS non-patients from IBS patients and
IBS patients who also have fibromyalgia corresponding
to a greater illness severity of IBS [38]. It has been
hypothesized that patients with mild-to-moderate IBS
often have more peripherally generated symptoms with
gut-based features (i.e., relieved by defecation worse with
eating, intermittent, crampy abdominal pain), whereas
patients with more severe and painful IBS tend to have
more noxious, continuous, and severe symptoms with
psychosocial and somatic comorbidities, thus reflecting
the greater central nervous system contribution to their
illness experience [38]. Furthermore, this concept applies
across various medical conditions, such as fibromyalgia,
chronic fatigue syndrome, inflammatory bowel disease,
or other chronic pain conditions, so much so that when
a condition is severe, it is associated with more symp-
toms of greater intensity [38]. Thus, there is a clinical
association of severity with psychosocial and medical
comorbidities for these functional conditions. It is beyond
the scope of this study to investigate on the multiple
pathophysiological link between IBS and FMS. For in-
stance, in both diseases, it has been shown that primary
and secondary hyperalgesia are maintained by central
sensitization, through tonic nociceptive input from per-
ipheral afferents [39,40]. In addition, conditioned pain
modulation (pain-inhibit-pain mechanisms - CPM) is
decreased in both IBS [15,16,41] and FMS [42-44].
Moreover, hyperalgesia is associated with decreased
CPM in patients with IBS [4], which may result from or
contribute to central sensitization, and may predispose
to the development of other chronic pain syndromes(e.g. IBS leading to FMS). Another possibility is the
contribution of psychological factors to altered pain
processing in both diseases.
On the other hand an explanation for graduated hyper-
sensitivity in regard to severity could be the involvement
of alternative descending pain-modulatory pathways,
which are activated through painful somatic stimuli (due
to FMS) and hence attenuate incoming visceral nocicep-
tive information. Conversely, this mechanism can work
vice versa for attenuating somatic perception. Another
possibility is viscera-somatic conversion at the spinal level
[45], which can also explain the observed phenomena.
Given this hypothesis, severity in IBS can be seen as a
multi-determined concept that integrates peripheral and
central biological processes as they affect symptoms.
Limitations of the study
There are several limitations in this study. The first is
that discomfort threshold was defined as the first stimulus
(electrical stimulus or rectal pressure) that induced a per-
ception score of ≥5. One could argue that these are levels
at which only low-threshold mechanoreceptors respond
with the possibility of having a ceiling effect in our thresh-
olds data. However there are considerable differences in
definitions used for discomfort or pain thresholds among
laboratories. Moreover, we performed less biased proto-
cols to make the stimulus unpredictable to the subject
[46] aiming to reduce psychological bias. However, it is
well known that IBS patients may be particularly prone to
such bias due to hypervigilance and anticipatory anxiety,
even though it is to be established if this anxiety is a cause
or consequence of increased visceral perception [47].
Then, the use of standard distension protocols and per-
ception assessment methods in all centres would be
desirable.
The second one is the lack of HC to confirm in our
patients the expected somatic and visceral hypersensitiv-
ity, although the main aim of the study was to evaluate
the differences among well selected IBS patients on the
basis of illness severity with or without FMS; another
limitation is that nearly two-thirds of the study partici-
pants were female and no men were present in severe
IBS with concomitant FMS. In fact, we were able to
enroll a smaller number of patients, only women, with
both IBS and FMS due to the known striking prevalence
of women in this group [48]. Nevertheless, the impact of
gender and age on somatic and visceral perception was
taken into account and we demonstrated that was not
significantly relevant on our results. This finding confirms
previous studies in which the correlation between symp-
tom severity and rectal sensitivity was similar in male and
female patients with IBS [18]. Interestingly, differences
in brain activation have been reported between men
and women with IBS [18,49,50], where female patients
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of a pain facilitation circuit; whereas male patients showed
increased activity in regions that could be involved in pain
inhibition. These observations have led some investigators
to believe that estrogen is a pronociceptive hormone
responsible for the increased pain sensitivity of females.
However, this notion has been difficult to prove in
women, because the data have generally shown an anti-
nociceptive action of estrogen in both normal females
and in those suffering from chronic pain [51-53].
Finally, based on the current design, we were unable to
identify the proposed mechanisms that underlie visceral
and somatic changes across different IBS severity.Conclusion
This study demonstrated a significant association between
altered rectal perception and severity of IBS; however,
the increase in cutaneous perception to electric stimuli
along with the severity of IBS failed to reach statistical
significance. The presence of FMS influences both somatic
and visceral perception. Although nowadays the exact
pathophysiological mechanisms underlying IBS still remain
elusive, this study suggests that the IBS patient population
may cluster into subgroups that are characterized by dif-
ferent degrees of severity and by the presence of somatic
comorbidities such as FMS in which possibly a unique
set of pathophysiologic mechanisms are present. Further
studies on somatic and visceral sensitivity in IBS patients
affected by different degrees of severity and FMS including
both a patient group with FMS only and a control group
with healthy volunteers are clearly needed for a better
pathophysiological understatement and management of
these syndromes.
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